just fyi: AOBO/Amerian Bioengineering CEO interview now posted on CEOcast.com. (can require free registration to listen to)."American Oriental Bioengineering, Inc. is a leading Chinese nutracuetical company that uses proprietary processes for producing soybean protein peptide more efficiently than traditional extracting techniques. These techniques are used to manufacture and formulate supplemental and medicinal products. Soybean peptides are used widely in general food, health food products, medicines and etc. The Company sees significant opportunities for the marketing of these soybean products and many of their other bioengineer products.".Note: I find CEOcast.com very useful--in spite of the fact that they are compensated by the companies that they cover. They basically serve as a brief, phone-interview-of-the-CEO introduction to a (usually very small) company. Same interview format for each company interviewed......they have to, since they do several a day. But this tends to keep it short and no-nonsense or hype.This was the first interview I've listened to that was interpreted (i.e, the CEO was speaking in Chinese from China). Thus, it takes longer than 'necessary' for those of us who don't speak Chinese. However, for those who do, you hear the actual CEO un-edited, which I would think is always a plus in trying to gauge his measure. (I also wouldn't mind at all if any native Chinese speaker would post a word or two about whether they picked up anything in his interview that the interpreter didn't pass on; it often happens!!)Currently soybean protein production is not their primary revenue driver; but they expect that to start changing by the end of 2003. Their emphasis seems to be to apply modern extraction and production techniques in order to make traditional (and increasingly non-traditional) Chinese therapeutics.also, a PR from last week:"Press Release Source: American Oriental Bioengineering Inc.AOBO Predicts Record Second Quarter and Half Year Profit GrowthWednesday July 30, 12:00 pm ETHONG KONG, July 30 /PRNewswire-FirstCall/ -- American Oriental Bioengineering Inc. (OTC Bulletin Board: AOBO - News; the 'Company') today announces that the Company projects a record second quarter and half year profit growth in its forth coming second quarter result announcement.ADVERTISEMENTShujun Liu, Chairman and CEO of the Company stated, "The soybean protein peptide products acquired at the beginning of this year has contributed significant revenue and profit growth for the Company. Together with the sales growth of our existing products, we predict a record second quarter and half year profit growth. Looking forward, we will focus on penetrating our existing products and soybean protein peptide products into new overseas markets to sustain continuous Company growth"About American Oriental Bioengineering, Inc.AOBO is a leading Chinese nutracuetical company that uses proprietary processes for producing soybean protein peptide more efficiently than traditional extracting techniques. These techniques are used to manufacture and formulate supplemental and medicinal products. Soybean peptides are used widely in general food, health food products, medicines and etc. The Company sees significant opportunities for the marketing of these soybean products and many of their other bioengineer products.Safe Harbor StatementExcept for the historical statements made herein, the statements made in this release are forward-looking statements, including. Risk factors that could cause actual results to differ materially from those projected in forward-looking statements include, but are not limited to, general business conditions, managing growth, and political and other business risks. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risks and other factors detailed in the Company's reports filed with the Securities and Exchange Commission.Source: American Oriental Bioengineering Inc.AOBO.OB 1.90 0.00JP
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings